Delaware
|
|
04-3561634
|
(State or other jurisdiction of incorporation or
organization) |
|
(I.R.S. Employer Identification No.)
|
675 West Kendall Street
Cambridge, Massachusetts
|
|
02142
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Large accelerated filer
x
|
Accelerated filer
o
|
Non-accelerated filer
o
(Do not check if a smaller reporting company)
|
Smaller reporting company
o
|
|
|
|
|
|
|
|
|
|
|
||
Title of securities to be registered
|
|
Amount
to be registered(1) |
|
Proposed
maximum offering price per share(3) |
|
Proposed
maximum aggregate offering price(3) |
|
Amount of
registration fee |
|
||
Common stock, par value $0.0001 per share
|
|
4,250,000(2)
|
|
|
$10.93
|
|
$46,452,500
|
|
|
$4,678
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MOMENTA PHARMACEUTICALS, INC.
|
|
|
|
|
|
By:
|
/s/ Craig A. Wheeler
|
|
Name: Craig A. Wheeler
|
|
|
Title: President and Chief Executive Officer
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/ Craig A. Wheeler
|
|
President, Chief Executive Officer and Director
|
|
August 8, 2016
|
|
Craig A. Wheeler
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
|
|
/s/ Richard P. Shea
|
|
Senior Vice President and Chief Financial Officer
|
|
August 8, 2016
|
|
Richard P. Shea
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
|
|
/s/ James R. Sulat
|
|
Chairman of the Board and Director
|
|
August 8, 2016
|
|
James R. Sulat
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Marsha H. Fanucci
|
|
Director
|
|
August 8, 2016
|
|
Marsha H. Fanucci
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Bruce L. Downey
|
|
Director
|
|
August 8, 2016
|
|
Bruce L. Downey
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Georges Gemayel
|
|
Director
|
|
August 8, 2016
|
|
Georges Gemayel
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Jose-Carlos Gutierrez-Ramos
|
|
Director
|
|
August 8, 2016
|
|
Jose-Carlos Gutierrez-Ramos
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Thomas P. Koestler
|
|
Director
|
|
August 8, 2016
|
|
Thomas P. Koestler
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Elizabeth Stoner
|
|
Director
|
|
August 8, 2016
|
|
Elizabeth Stoner
|
|
|
|
|
|
|
|
|
|
|
|
/s/ Steven C. Gilman
|
|
Director
|
|
August 8, 2016
|
|
Steven C. Gilman
|
|
|
|
|
Exhibit
Number |
|
Description
|
|
|
|
4.1(1)
|
|
Third Amended and Restated Certificate of Incorporation of the Registrant
|
|
|
|
4.2(2)
|
|
Certificate of Designations of Series A Junior Participating Preferred Stock, dated November 8, 2005
|
|
|
|
4.3(3)
|
|
Third Amended and Restated By-laws of the Registrant
|
|
|
|
4.4(4)
|
|
Specimen certificate evidencing shares of common stock of the Registrant
|
|
|
|
4.5(5)
|
|
Investor Rights Agreement, dated as of July 25, 2006, by and between Novartis Pharma AG and the Registrant
|
|
|
|
5.1
|
|
Opinion of Latham & Watkins LLP
|
|
|
|
23.1
|
|
Consent of Ernst & Young LLP
|
|
|
|
23.2
|
|
Consent of Latham & Watkins LLP (included in Exhibit 5.1)
|
|
|
|
24.1
|
|
Power of Attorney (included on signature page)
|
|
|
|
99.1(6)
|
|
Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan (as amended and restated)
|
August 8, 2016
|
John Hancock Tower, 27th Floor
200 Clarendon Street
Boston, Massachusetts 02116
Tel: +1.617.948.6000 Fax: +1.617.948.6001
www.lw.com
FIRM / AFFILIATE OFFICES
Barcelona
Beijing
Boston
Brussels
Century City
Chicago
Dubai
Düsseldorf
Frankfurt
Hamburg
Hong Kong
Houston
London
Los Angeles
Madrid
Milan
|
Moscow
Munich
New Jersey
New York
Orange County
Paris
Riyadh
Rome
San Diego
San Francisco
Shanghai
Silicon Valley
Singapore
Tokyo
Washington, D.C.
|
Re:
|
Registration Statement on Form S-8; 4,250,000 shares of common stock, par value $0.0001 per share, of Momenta Pharmaceuticals, Inc.
|
August 8, 2016
Page 2
|
Very truly yours,
|
/s/ LATHAM & WATKINS LLP
|
|
Consent of Independent Registered Public Accounting Firm
|
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Momenta Pharmaceuticals, Inc. 2013 Incentive Award Plan of our reports dated February 26, 2016, with respect to the consolidated financial statements of Momenta Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Momenta Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2015, filed with the Securities and Exchange Commission.
|
|
|
|
/s/ Ernst & Young LLP
|
|